Mopetia (Paliperidone)

Paliperidone blocks dopamine D2 receptors and serotonin 5‑HT2A receptors while partially stimulating other serotonergic sites. This combined antagonism and partial agonism balances dopaminergic and serotonergic pathways, which reduces hallucinations, delusions, and mood swings in schizophrenia and schizoaffective disorder.

The dose of Mopetia is determined individually by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Healthcare professionals adjust the injection strength and frequency according to approved labeling and patient needs.

Safety data for paliperidone in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Mopetia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required), and necessary import documentation.

Paliperidone is the primary active metabolite of risperidone and shares a similar receptor profile, but it offers a longer half‑life and is available as a once‑monthly intramuscular injection. This can improve adherence compared with daily oral risperidone, while maintaining comparable efficacy in controlling psychotic symptoms.

Mopetia must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. If temporary temperature excursions occur, consult the product’s stability guidelines before use.

Mopetia is given as an intramuscular injection by a qualified healthcare professional. The injection is typically administered into the gluteal or deltoid muscle, following aseptic technique and the dosing schedule prescribed by the treating clinician.

Serious adverse reactions include neuroleptic malignant syndrome, a potentially fatal condition with high fever and muscle rigidity, tardive dyskinesia, which can cause persistent involuntary movements, and seizures. Patients should be monitored closely for these events, and any signs should prompt immediate medical evaluation.

Mopetia is contraindicated in patients with known hypersensitivity to paliperidone or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled cardiovascular disease, or a history of neuroleptic malignant syndrome. The drug should be avoided in patients for whom the risks outweigh the therapeutic benefits.